[ET Net News Agency, 6 November 2019] Goldman Sachs raised its target price for CSPC
Pharmaceutical (01093) to HK$25.8 from HK$18.9 and maintained its "buy" rating.
CSPC hosted its first open day on 3- October, unveiling details of major R&D programs
and reviewing its commercialization achievements. The research house said this milestone
event: (1) marks CSPC's increasing emphasis on innovative drug R&D in its long-term growth
strategy, with a multi-modality R&D platform that builds on proprietary technologies and
talent recruited globally, (2) reinforces the company's commitment to strong execution and
enhancing corporate governance, (3) enables investors to better assess CSPC's pipeline
value given better visibility and transparency of clinical development progress.
Goldman raised 2020-2021 EPS forecasts by 0.5%/1.5% to factor in the potential launch of
innovative drugs. (KL)